

CURRICULUM VITAE AND LIST OF PUBLICATIONS

1. Personal Details

Family name, first name: Moran-Gilad, Jacob (Kobby)

Former name: Gilad, Jacob

Date and place of birth: 09/02/1975

E-mail address: giladko@post.bgu.ac.il

2. Academic Education

First degree: B. Med. Sci.

1995, Faculty for Health Sciences, Ben-Gurion University
(magna cum laude)

Second degree: M.P.H

2013, Faculty for Health Sciences, Ben-Gurion University

Third degree: M.D.

1999, Faculty for Health Sciences, Ben-Gurion University

Name of advisors: Prof. Francisc Schlaeffer & Prof. Avi Porath

Title of thesis: G-CSF for prevention of febrile neutropenia

3. Professional Training

2010-2013 – Residency in Public Health, Public Health Services' Directorate,
Ministry of Health, Jerusalem.

2010-2011 – Fellowship, United Kingdom's Health Protection Agency,
Directorate of the Centre for Infections (CfI), Colindale, London.

2005-2008 – Residency in Clinical Microbiology, Clinical Microbiology
Laboratory, Tel-Aviv Sourasky Medical Center, Tel-Aviv.

1999-2000 - Internship, Tel-Aviv Sourasky Medical Center and Soroka
University Medical Center.

4. Board Certification and Registration

Clinical Microbiology	Year: 2008 with distinction
Public Health	Year: 2013 with distinction

5. Employment History (in chronological order)

- 2016-present *Associate Professor (Physician-Researcher Tenure Track)*, Department of Health Systems Management, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
- 2016-present *Clinical Microbiology consultant*, Hospital Management, Soroka University Medical Center, Beer-Sheva, Israel
- 2016-present *Senior Advisor for Public Health Microbiology*, Public Health Services, Ministry of Health, Israel
- 2014 - 2015 *Chief Scientist for Medical Research*, Israeli Ministry of Defense
- 2011 - present *Honorary Consultant* in public health microbiology, Microbiology Services Division, UK Health Protection Agency (now PHE - Public Health England), London, United Kingdom
- 2011- present *National Microbiology Focal Point*, Public Health Services, Ministry of Health.
- 2011- 2013 *Head of Microbiology Cooperation*, Public Health Services, Ministry of Health.
- 2010 – 2011 *Senior Fellow* in Public Health Microbiology Strategy, Centre for Infections' Directorate, UK Health Protection Agency, London.
- 2005 – 2009 *Clinical microbiologist*, Tel-Aviv Sourasky Medical Center, Tel-Aviv

6. Academic Appointments (in chronological order)

- 2016 – present – **Academic Staff Member (Tenure track)**, Department of Health Systems Management, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
- 2016 - present – *Associate Professor of Clinical Microbiology (Clinical track)*, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
- 2014 – 2015 – *Adjunct Associate Professor of Clinical Microbiology (Clinical*

track), Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel

6. Scientific Publications

Refereed articles in scientific journals

1. Borer A, Riesenberk K, Uriel N, Gilad J, Porath A, Weber G, Schlaeffer F. Infective endocarditis in a tertiary-care hospital in southern Israel. Public Health Reviews, 1998; 26: 317-330 (not ranked).
2. Gilad J, Riesenberk K, Mermershtain W, Borer A, Porath A, Schlaeffer F. Granulocyte-colony stimulating factor (G-CSF) for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of southern Israel. Supportive Care in Cancer 1999; 7: 260-264 (IF=2.535; JR=8/65; Q= Q1; CI=1).
3. Borer A, Gilad J, Haikin H, Riesenberk K, Porath A, Schlaeffer F. Clinical features and costs of care for hospitalized adults with primary Epstein-Barr virus infection. American Journal of Medicine, 1999; 107: 144-148 (IF=5.610; JR=13/151; Q=Q1; CI=4).
4. Gilad J, Borer A, Riesenberk K, Peled N, Schlaeffer F. Epidemiology and ethnic distribution of drug-resistant tuberculosis in southern Israel 1992-1997: The impact of immigration. Chest, 2000; 117: 738-743 (IF=5.940; JR=6/58; Q=Q1; CI=18)
5. Crystal E, Borer A, Gilad J, Haick I, Weber G, Alkan M, Riesenberk K, Schlaeffer F, Battler A, Ilia R, Leor J. Significant prevalence of bacteremia and sepsis in cardiac patients treated with intra-aortic balloon pump counterpulsation. American Journal of Cardiology, 2000; 86: 1281-1284 (IF=3.154; JR=43/124; Q=Q2; CI=9).

6. Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, Riesenber K, Schlaeffer F. Clinical significance of extended-spectrum beta-lactamase producing *Enterobacteriaceae* in nosocomial bacteremia. *Scandinavian Journal of Infectious Diseases*, 2001; 33: 188-193 (IF=1.366; JR=66/83;Q= Q4; CI=45).
7. Gilad J, Borer A, Riesenber K, Peled N, Klein M, Schlaeffer F. Polymicrobial polyarticular septic arthritis: A rare clinical entity. *Scandinavian Journal of Infectious Diseases*, 2001;33:381-383 (IF=1.366; JR=66/83;Q= Q4; CI=2).
8. Borer A, Meirson H, Peled N, Porat N, Dagan R, Fraser D, Gilad J, Zehavi N, Yagupsky P. Antibiotic-resistant pneumococci carried by young children do not appear to disseminate to adult members of a closed community. *Clinical Infectious Diseases*, 2001; 33: 433-444 (IF=8.736; JR=2/83;Q= Q1; CI=22).
9. Borer A, Gilad J, Meydan N, Riesenber K, Schlaeffer F, Alkan M, Schlaeffer P. Impact of active monitoring of infection control practices on deep sternal infection after open-heart surgery. *Annals of Thoracic Surgery*, 2001; 72: 515-520 (IF=2.975; JR=35/199; Q=Q1; CI=21).
10. Borer A, Gilad J, Menashe G, Peled N, Riesenber K, Schlaeffer F. Extended-spectrum beta-lactamase-producing *Enterobacteriaceae* strains in community-acquired bacteremia in southern Israel. *Medical Science Monitor*, 2002; 28: CR44-47 (IF=1.405; JR=92/124;Q= Q3; CI=not ranked).
11. Borer A, Gilad J, Yagupsky P, Peled N, Shprecher-Levy H, Porat N, Trefler R, Riesenber K, Shipman M, Schlaeffer F. Community-acquired methicillin-resistant *Staphylococcus aureus* in institutionalized adults with developmental disabilities. *Emerging Infectious Diseases*, 2002; 8: 966-970 (IF=6.994; JR=4/83; Q=Q1; CI=38).

12. Smolyakov R, Borer A, Riesenberk K, Schlaeffer F, Alkan M, Porath A, Rimar D, Almog Y, Gilad J. Nosocomial multi-drug resistant *Acinetobacter baumannii* bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. *Journal of Hospital Infection*, 2003; 54: 32-38 (IF=2.655; JR=35/83; Q=Q2; CI=79).
13. Levi I, Gaspar N, Riesenberk K, Porath A, Yerushalmi R, Gilad J, Schlaeffer F. Iron-deficiency anemia related to *Ancylostoma duodenale* infection among Ethiopian immigrants to Israel. *Harefuah*, 2003; 142: 606-608. (not ranked).
14. Borer A, Gilad J, Hyam E, Schlaeffer F, Schlaeffer P, Eskira S, Aloni P, Wagshal A, Katz A. Prevention of cardiac antiarrhythmic device-associated infections by implementation of a comprehensive infection control program. *Infection Control and Hospital Epidemiology*, 2004; 25: 492-497 (IF=3.669; JR=24/172; Q= Q1; CI=15).
15. Borer A, Gilad J, Meydan N, Schlaeffer P, Riesenberk K, Schlaeffer F. Impact of regular attendance by infectious disease specialists on the management of hospitalized adults with community-acquired febrile syndromes. *Clinical Microbiology and Infection*, 2004; 10: 911-916 (IF=4.575; JR=10/83; Q=Q1; CI=12).
16. Gilad J, Eskira S, Schlaeffer F, Vorobiov M, Marcovici, A, Tovbin D, Borer A. Surveillance of chronic hemodialysis-associated infections in southern Israel. *Clinical Microbiology and Infection*, 2005; 11: 547-552 (IF=4.575; JR=10/83; Q=Q1; CI=5).
17. Gilad J, Moran L, Meydan N, Schlaeffer F, Borer A. Antibiotic drug advertising in medical journals: another target for prevention of antimicrobial resistance? *Scandinavian Journal of Infectious Diseases*, 2005; 37: 910-912 (IF=1.366; JR=66/83; Q= Q4; CI=3).

18. Eskira S, Gilad J, Schlaeffer P, Hyam E, Peled N, Riesenber K, Schlaeffer F, Borer A. Reduction of blood culture contamination rate by an educational intervention. *Clinical Microbiology and Infection*, 2006; 12: 818-821 (IF=4.575; JR=10/83; Q=Q1; CI=21).
19. Smolikov A, Smolyakov R, Riesenber K, Schlaeffer F, Borer A, Cherniavsky E, Gabriel A, Gilad J. Prevalence and clinical significance of pleural microbubbles in computed tomography of thoracic empyema. *Clinical Radiology*, 2006; 61: 513-519 (IF=2.151; JR=50/124; Q= Q2; CI=7).
20. Gilad J, Borer A, Smolyakov R Riesenber K, Schlaeffer F, Levy R. Impaired neutrophil functions in the pathogenesis of an outbreak of recurrent furunculosis caused by methicillin-resistant *Staphylococcus aureus* among mentally-retarded adults. *Microbes and Infection*, 2006; 8; 1801-1805 (IF=2.291; JR=46/83; Q= Q3; CI=4).
21. Hadad E, Pirogovsky A, Bartal C, Gilad J, Barnea A, Itzhaky S, Grotto I, Balicer R, Schwartz E. An outbreak of leptospirosis among Israeli troops in the Jordan River. *American Journal of Tropical Medicine and Hygiene*, 2006; 75: 127-131 (IF=2.453; JR= 4/19; Q= Q1; CI=16).
22. Gilad J, Giladi M, Poch F, Aharoni Y, Schwartz D. "All-in-one-plate" E-test and disk-diffusion co-testing for multi-resistant *Acinetobacter baumannii*. *European Journal of Clinical Microbiology and Infectious Diseases*, 2006; 25: 799-802 (IF=2.857; JR= 29/83; Q= Q2; CI=4).
23. Gilad J, Giladi M, Schwartz D. *Candida albicans* masquerading as gram-negative bacilli in the clinical laboratory. *Scandinavian Journal of Infectious Diseases*, 2007; 39: 907-910 (IF=1.366; JR=66/83; Q= Q4; CI=2).

24. Borer A, Gilad J, Porat N, Megreleshvilli R, Saidel-Odes L, Peled N, Eskira S, Schlaeffer F, Almog Y. Impact of 4% chlorhexidine whole-body washing on multidrug-resistant *Acinetobacter baumannii* skin colonisation among patients in a medical intensive-care unit. *Journal of Hospital Infection*, 2007; 67: 149-155 (IF=2.655; JR=35/83; Q=Q2; CI=27).
25. Kopilov U, Admon G, Borer A, Schlaeffer F, Aviram EE, Gilad J. Auditing and benchmarking of azithromycin utilization in primary-care military clinics. *Military Medicine*, 2007; 172: 1065-1070 (IF=0.848; JR= 90/151;Q= Q3; CI=1).
26. Moran L, Gilad J. From folklore to scientific evidence: Breast-feeding and wet-nursing in the Islam - The case of non-puerperal lactation. *International Journal of Biomedical Sciences*, 2007; 3: 251-7. (not ranked)
27. Moran Gilad J, Carmeli Y, Schwartz D, Navon-Venezia S. Laboratory evaluation of the CHROMagarKPC medium for identification of carbapenem-nonsusceptible Enterobacteriaceae. *Diagnostic Microbiology and Infectious Diseases*, 2011; 70: 565-567 (IF=2.450; JR=43/83;Q= Q3; CI=9).
28. Lackenby A, Moran Gilad J, Pebody R, Miah S, Calatayud L, Bolotin S, Vipond I, Muir P, Guiver M, McMenamin J, Reynolds A, Moore C, Gunson R, Thompson C, Galiano M, Bermingham A, Ellis J, Zambon M. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. *Euro Surveillance* 2011; 16: pii=19784 (IF=5.983; JR=7/83; Q=Q1; CI=32)
29. Adler A, Navon-Venezia S, Moran Gilad J, Marcos J, Schwartz D, Carmeli Y. Laboratory and clinical evaluation of screening agar plates for the detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. *Journal of Clinical Microbiology*, 2011; 49: 2239-42 (IF=3.631; JR=36/123;Q= Q2; CI=50).

30. Levine H, Mimouni D, Bader T, Block C, Glickman D, Ben Dov D, Moran-Gilad J, Hartal M (IDF Expert Panel on Skin and Soft Tissue Infection). Prevention and treatment of invasive skin infections in the IDF: findings and recommendations of multidisciplinary expert panel. *Journal of Israeli Military Medicine*, 2012; 9: 12-17 (Not ranked).
31. Moran-Gilad J, Schwartz D, Navon-Venezia S, Carmeli Y. Laboratory Evaluation of the ESwab Transport System for the Recovery of Multidrug-Resistant *Acinetobacter baumannii*. *European Journal of Clinical Microbiology and Infectious Diseases* 2012; 31: 1429-33 (IF=2.857; JR=29/83; Q= Q2; CI=1).
32. Moran-Gilad J, Chand M, Brown C, Shetty N, Morris G, Green J, Jenkins C, Ling C, McLauchlin J, Harrison T, Goddard N, Brown K, Bolton E, Zambon M on behalf of HPA Microbiology Services Olympics Planning Group. Microbiological Aspects of Public Health Planning and Preparedness for the 2012 Olympics. *Epidemiology & Infection* 2012; 15: 1-10 (IF=2.515; JR=46/172; Q= Q2; CI=6).
33. Moran-Gilad J, Lazarovitch T, Mentasti M, Harrison T, Weinberger M, Mordish Y, Mor Z, Stocki T, Anis E, Sadik C, Amitai Z, Grotto I. Humidifier-associated paediatric Legionnaires' disease, Israel, February 2012 . *Euro Surveill* 2012;17(41):pii=20293. (IF=5.983; JR=7/83; Q=Q1; CI=9).
34. Saunders NA, Zambon M, Sharp I, Siddiqui R, Bermingham A, Ellis J, Vipond IB, Sails A, Moran-Gilad J, Marsh P, Guiver M. Guidance on the development and validation of diagnostic tests that depend on nucleic acid amplification and detection. *Journal of Clinical Virology* 2013; 56: 260-270 (IF=2.647; JR= 16/33; Q= Q2; CI=9).
35. Moran-Gilad J, Levine H, Schwartz E, Bartal C, Hartal M, Schwaber MJ, Ostfeld I. Post exposure prophylaxis of tick-borne relapsing fever: Lessons learned from recent outbreaks in Israel. *Vector-Borne and Zoonotic Diseases* 2013; 13: 1-7. (IF=1.956; JR=71/172; Q= Q2; CI=3).

36. Kessous R, Aricha-Tamir B, Sheizaf B, Shteiner N, Moran-Gilad J, Weintraub AY. Clinical and microbiological characteristics of Bartholin's gland abscesses. *Obstetrics & Gynecology* 2013; 122: 794-799. (IF=5.126; JR=2/80; Q=Q1; CI=5)
37. Weinberger M, Lerner L, Valinsky L, Moran-Gilad J, Nissan I, Agmon V, Peretz C. Sharp increase with high pediatric burden of *Campylobacter* infection in Israel. *Emerging Infectious Diseases* 2013; 19: 1828-1831. (IF=6.994; JR=4/83; Q=Q1; CI=3).
38. Anis E, Kopel E, Singer SR, Kaliner E, Moerman L, Moran-Gilad J, Sofer D, Manor Y, Shulman LM, Mendelson E, Gdalevich M, Lev B, Gamzu R, Grotto I. Insidious reintroduction of wild poliovirus into Israel, 2013. *Euro Surveill.* 2013;18(38):pii=20586. (IF=5.983; JR=7/83; Q=Q1; CI=17).
39. Moran-Gilad J, Mentasti M, Lazarovitch T, Huberman Z, Stocki T, Sadik C, Shahar T, Anis E, Harrison TG, Grotto I. Molecular Epidemiology of Legionnaires' Disease, Israel, 2006-2011. *Clinical Microbiology and Infection* 2014; 20: 690-696 (IF=4.575; JR=10/83; Q=Q1; CI=2).
40. Kaliner E, Moran-Gilad J, Grotto I, Somekh E, Gdalevich M, Shimron E, Amikam Y, Lev B, Gamzu R. Silent Reintroduction of Wild-type Poliovirus to Israel, 2013 – Risk Communication Challenges in an Argumentative Atmosphere. *Euro Surveill.* 2014;19 (7):pii=20703 (IF=5.983; JR=7/83; Q=Q1; CI=6).
41. Hindiyeh M, Moran-Gilad J, Sofer D, Manor Y, Ram D, Shulman LM, Mendelson E. Development and Validation of a Quantitative RT-PCR Assay for Investigation of Wild-Type Poliovirus 1 Reintroduced into Israel. *Euro Surveill.* 2014;19 (7):pii=20710 (IF=5.983; JR=7/83; Q=Q1; CI=4).
42. Manor Y, Shulman LM, Hindiyeh M, Sofer D, Gdalevitz M, Moran-Gilad J, Kaliner E, Grotto I, Gamzu R, Mendelson E. Intensified Environmental Surveillance Supporting the Response to Wild-Type Poliovirus type 1 Silent

- Circulation in Israel, 2013. *Euro Surveill.* 2014;19 (7):pii=20708 (IF=5.983; JR=7/83; Q=Q1; CI=4).
43. Shulman L, Gavrilin E, Jorba J, Martin J, Burns C, Manor Y, Moran-Gilad J, Sofer D, Hindiyeh M, Gamzu R, Mendelson E, Grotto I, Genotype-Phenotype Identification (GPI) Group. Molecular Epidemiology of Silent Introduction and Sustained Transmission of Wild Poliovirus Type 1, Israel, 2013. *Euro Surveill.* 2014;19 (7):pii=20709 (IF=5.983; JR=7/83; Q=Q1; CI=11).
44. Moran-Gilad J, Adler A, Schwartz D, Navon-Venezia S, Carmeli Y. Laboratory Evaluation of Different Agar Media for Isolation of Carbapenem-Resistant *Acinetobacter spp.* *European Journal of Clinical Microbiology and Infectious Diseases*, 2014; 33: 1909-1913. (IF=2.857; JR= 29/83;Q= Q2; CI=1).
45. Shulman LM, Mendelson M, Anis E, Bassal R, Gdalevich M, Hindiyeh M, Kaliner E, Kopel E, Manor J, Moran-Gilad J, Ram D, Sofer D, Somekh E, Tasher D, Weil M, Gamzu R, Grotto I. Aspects of the Public Health Response to Silent Introduction and Sustained Transmission of Wild type 1 Poliovirus into Israel in 2013. *Journal of Infectious Diseases*, 2014; 210 Suppl 1: S304-S314. (IF=6.344; JR=5/83;Q= Q1; CI=5).
46. *Green HK, Charlett A, Moran-Gilad J, Fleming D, Durnall H, Thomas DRH, Cottrell S, Smyth B, Kearns C, Reynolds A, Smith GE, Elliot AJ, Ellis J, Zambon M, Watson JM, McMenamin J, Pebody RG. Harmonising influenza primary care surveillance in the United Kingdom: Piloting two methods to assess the timing and intensity of the seasonal epidemic across several general practice-based surveillance schemes and future implications. *Epidemiology & Infection* 2014; 15: 1-12 (IF=2.515; JR=46/172;Q= Q2; CI=2).
47. *Shulman LM, Martin J, Sofer D, Burns CC, Manor Y, Hindiyeh MY, Gavrilin E, Wilton T, Moran-Gilad J, Gamzu R, Mendelson E, Grotto I for the Genotype-Phenotype Identification (GPI) Group. Genetic Analysis and Characterization of Wild Poliovirus Type 1 during Sustained Transmission in

- a Population with >95% Vaccine Coverage, Israel 2013. *Clinical Infectious Diseases*, 2015; 60: 1057-1064 (IF=8.736; JR=2/83;Q= Q1; CI=5).
48. *Gur I, Shapira S, Katalan S, Rosner A, Baranes S, Grauer E, Moran-Gilad J, Eisenkraft A. Biphasic cuirass ventilation is better than bag-valve mask ventilation for resuscitation following organophosphate poisoning. *Toxicology Reports* 2015; 2: 40-45 (not ranked).
49. *Moran-Gilad J, Sintchenko V, Karlsmose S, Wolfgang WJ, Pettengill J, Strain E, Hendriksen RS on behalf of Working Group 4 (GMI-WG4). Proficiency Testing for Bacterial Whole Genome Sequencing: An End-User Survey of Current Capabilities, Requirements and Priorities. *BMC Infectious diseases*, 2015; 15: 174. (IF=2.690; JR= 33/83; Q=2; CI=1).
50. *Moran-Gilad J, Mendelson E, Burns CC, Bassal R, Gdalevich M, Sofer D, Oberste MS, Shulman LM, Kaliner E, Hindiyeh M, Mor O, Shahar L, Iber J, Yishay R, Manor J, Lev B, Gamzu R, Grotto I. Field Study of Fecal Excretion as a Decision Support Tool in Response to Silent Reintroduction of Wild-type Poliovirus 1 into Israel. *Journal of Clinical Virology*, 2015; 66: 51-55. (IF=2.647;JR= 16/33;Q= Q2; CI=2).
51. *Kaliner E, Kopel E, Anis E, Mendelson E, Moran-Gilad J, Shulman LM, Singer SR, Manor J, Somekh E, Rishpon S, Leventhal A, Rubin L, Tasher D, Honovich M, Moerman L, Shohat T, Bassal R, Sofer D, Gdalevich M, Lev B, Gamzu R, Grotto I. National public health response to the importation and silent transmission of wild poliovirus 1 in Israel, 2013. *Lancet Infectious diseases*, 2015;15:1236-1242 (IF=21.372; JR= 1/83; Q=1; CI=0).
52. *Moran-Gilad J, Prior K, Yakunin E, Harrison TG, Underwood A, Lazarovitch T, Valinsky L, Lück C, Krux F, Agmon V, Grotto I, Harmsen D. Design and Application of a Core Genome Multi-Locus Sequence Typing Scheme for Investigation of Legionnaires' Disease Incidents. *Euro Surveill* 2015;20(14):pii=21087 (IF=5.983; JR=7/83; Q=Q1; CI=0).

53. *Levcovich A, Lazarovitch T, Moran-Gilad J, Peretz C, Yakunin E, Valinsky L, Weinberger M. Complex Clinical and Microbiological Effects on Legionnaires' Disease Outcome: A Retrospective Cohort Study. BMC Infectious diseases, 2016; 16: 75 (IF=2.690; JR= 33/83; Q=2; CI=0).
54. *Yaari R, Kaliner E, Grotto I, Katriel G, Moran-Gilad J, Sofer D, Mendelson E, Miller E, Huppert A. Modeling the spread of polio in an IPV-vaccinated population; lessons learned from the 2013 silent outbreak in southern Israel. BMC Medicine 2016;14:95 (IF=8.005; JR=8/151;Q= Q1; CI=0).
55. *Lapid R, King R, Yakobson B, Shalom U, Moran-Gilad J. Wildlife Pathogen Surveillance in Israel to Inform Human and Animal Infectious Disease Control: a Prioritization Exercise. Israel Journal of Veterinary Medicine 2016;71:33-41 (IF=0.293; JR=117/138; Q=4; CI=0).
56. *Weinberger M, Moran-Gilad J, Rokney A, Davidov Y, Agmon V, Peretz C, Valinsky L. Molecular epidemiology of *Campylobacter jejuni* infection in Israel – a nationwide study. Clinical Microbiology and Infection 2016 (in press) (IF=4.575; JR=10/83; Q=Q1; CI=0).

Case reports

1. Gilad J, Borer A, Weksler N, Riesenber K, Schlaeffer F. Fatal necrotizing fasciitis caused by a toothpick injury. Scandinavian Journal of Infectious Diseases 1998; 30: 189-190 (IF=1.366; JR=66/83;Q= Q4; CI=7).
2. Gilad J, Borer A, Peled N, Riesenber K, Shnaider A, Schlaeffer F. *Enterococcus hirae* septicemia in a patient with end-stage renal disease undergoing hemodialysis. European Journal of Clinical Microbiology and Infectious Diseases,1998; 17: 576-577 (IF=2.857; JR= 29/83;Q= Q2; CI=15).
3. Gilad J, Borer A, Maimon N, Riesenber K, Klein M, Schlaeffer F. Failure of ciprofloxacin prophylaxis for ultrasound-guided transrectal prostatic biopsy in

the era of multi-resistant *Enterobacteriaceae*. Journal of Urology 1999; 161: 222 (IF=4.7;JR= 8/77; Q=Q1; CI=16).

4. Borer A, Metz I, Gilad J, Weksler N, Riesenber K, Weber G, Alkan M, Horowitz J. Massive pulmonary haemorrhage caused by leptospirosis successfully treated with nitric oxide inhalation and haemofiltration. Journal of Infection 1999; 38: 42-45 (IF=4.382; JR=13/83;Q= Q1; CI=20).
5. Gilad J, David A, Hertzanu Y, Flusser D, Wolak T, Levi I, Krugliak P. Endoscopic biliary sphincterotomy complicated by abscess formation in a simple renal cyst. Endoscopy 1999; 31: S5-6 (IF=5.634; JR=6/199; Q=Q1; CI=1).
6. Borer A, Gilad J, Sikuler E, Riesenber K, Schlaeffer F, Buskila D. Fatal *Clostridium sordellii* ischio-rectal abscess with septicaemia following ultrasound-guided transrectal prostatic biopsy. Journal of Infection 1999; 38: 128-129 (IF=4.382; JR=13/83;Q= Q1; CI=19).
7. Menashe G, Borer A, Gilad J, Horowitz J. Rhabdomyolysis after correction of severe hyponatremia. American Journal of Emergency Medicine, 2000; 18: 229-230 (IF=1.504; JR=11/24;Q= Q2; CI=9).
8. Gilad J, Borer A, Peled N, Riesenber K, Tager S, Appelbaum A, Schlaeffer F. Hospital-acquired *Brevundimonas vesicularis* septicemia following open-heart surgery. Scandinavian Journal of Infectious Diseases, 2000; 32: 90-91 (IF=1.366; JR=66/83;Q= Q4; CI=26).
9. Gilad J, Borer A, Hallel-Halevy D, Riesenber K, Schlaeffer F. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly-active antiretroviral therapy in an HIV-infected patient. Israeli Medical Association Journal, 2001; 3: 451-452 (IF=0.903; JR=93/150; Q=Q3; CI=25).
10. Smolyakov R, Riesenber K, Schlaeffer F, Borer A, Gilad J, Peled N, Alkan M. Streptococcal septic arthritis and necrotizing fasciitis in a couple of

intravenous drug users sharing needles. *Israeli Medical Association Journal*, 2002;4:302-303 (IF=0.903; JR=93/150; Q=Q3; CI=1).

11. Gilad J, Wolak A, Borer A, Benharroch D, Giladi M, Avidor B, Schlaeffer F. Isolated splenic cat-scratch disease in an immunocompetent adult woman. *Clinical Infectious Diseases*, 2003; 36: e10-13 (IF=8.736; JR=2/83; Q= Q1; CI=12).
12. Gilad J, Pirogovsky A, Bartal C. Unmasking of carnitine palmitoyltransferase deficiency during an acute asthma exacerbation complicated by rhabdomyolysis. *Military Medicine*, 2004; 169: 821-823 (IF=0.848; JR=90/151; Q= Q3; CI=1).
13. Etzion Y, Benharroch D, Saidel M, Riesenber K, Gilad J, Schlaeffer F. Atraumatic rupture of spleen associated with the hemophagocytic syndrome and isolated splenic peliosis. *Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS)*, 2005; 113: 555-557 (IF=1.933; JR=37/78; Q=Q2; CI=2).
14. Shalev A, Gilad J, Riesenber K, Borer A, Koval S, Schlaeffer F, Katz A. Conservative management of implantable cardioverter defibrillator related endocarditis due to *Bacillus spp*. *Infection*, 2007; 4: 114-117 (IF=2.294; JR=45/83; Q= Q3; CI=2).
15. Ostfeld I, Hod-Feins R, Rouvio O, Dorfman L, Moran-Gilad J. Primary gastric lymphoma in a soldier presenting as acute gastrointestinal bleeding. *Disaster and Military Medicine*, 2015 (in press) (not ranked).

Editorials and invited reviews and other reviews

1. Moran L, Gilad J, Schlaeffer F. Bioterrorism: Clear and immediate danger? [review]. *Harefuah*, 2000; 139: 36-41. (Not ranked)
2. Borer A, Gilad J, Sikuler E, Riesenber K, Schlaeffer F, Buskila D. Fatal *Clostridium sordellii* ischio-rectal abscess with septicaemia following

- ultrasound-guided transrectal prostatic biopsy [invited review]. *Urology Reviews*, 2000;4:12-13. (Not ranked)
3. Borer A, Gilad J, Schlaeffer F. Management of primary Epstein-Barr virus infection in immunocompetent patients [invited review]. *Current Treatment Options in Infectious Diseases*, 2001; 3: 67-77. (Not ranked)
 4. Gilad J, Walfisch A, Borer A, Schlaeffer F. Gender differences and sex-specific manifestation of infection with the human immunodeficiency virus among women [review]. *European Journal of Obstetrics & Gynaecology and Reproductive Biology*, 2003; 109: 199-205 (IF=1.662; JR=49/80; Q=Q3; CI=11).
 5. Gilad J, Wolak A, Borer A, Benharroch D, Giladi M, Avidor B, Schlaeffer F. Isolated splenic cat-scratch disease in an immunocompetent adult woman [invited]. *Infectious Disease Review Series*, 2003; 4: 18-20. (Not ranked).
 6. Gilad J, Borer A. Prevention of catheter-related bloodstream infection in the neonatal intensive-care setting [invited review]. *Expert Review of Anti-Infective Therapy*, 2006; 4: 861-873 (IF=3.542; JR=59/253; Q=Q1).
 7. Gilad J, Harary I, Dushnitsky T, Schwartz D, Amsalem Y. *Burkholderia mallei* and *Burkholderia pseudomallei* as bioterrorism agents: National aspects of emergency preparedness [review]. *Israeli Medical Association Journal*, 2007; 9: 499-503 (IF=0.903; JR=93/150; Q=Q3; CI=24).
 8. Gilad J, Amsalem Y, Schwartz D. Clinical features and laboratory diagnosis of infection with the potential bioterrorism agents *Burkholderia mallei* and *Burkholderia pseudomallei* [invited review]. *International Journal of Biomedical Sciences*, 2007; 3: 144-152. (Not ranked)

9. Gilad J. Developments in diagnosis and management of melioidosis and glanders [invited review]. *Recent Patents on Anti-Infective Drug Discovery*, 2007; 2: 233-241. (Not ranked)
10. Gilad J., Carmeli Y. Treatment options of multidrug-resistant *Acinetobacter* species. [invited review]. *Drugs*, 2008; 68: 165-189 (IF=4.883, JR=24/253, Q=Q1; CI=32).
11. Moran Gilad J., Tusk-Helerman L, Fogel I, Harary I, Dushnitsky T. Ricin and Abrin as potential bio-weapons [invited review]. *Journal of Israeli Military Medicine*, 2011; 7: 124-127 (Not ranked)
12. Tusk-Helerman L, Fogel, Yerushalmi G, Moran Gilad J. Viral hemorrhagic fevers [invited review]. *Journal of Israeli Military Medicine*, 2011; 7: 128-132. (Not ranked)
13. *Moran-Gilad J., Kaliner E, Gdalevich M, Grotto I. Public Health Response to the Silent Reintroduction of Wild Poliovirus to Israel, 2013-2014 [invited review]. *Clinical Microbiology and Infection* 2016 (in press) (IF=4.575; JR=10/83; Q=Q1; CI=0).

Letters

1. Gilad J., Levy I, Riesenber K, Schlaeffer F. Fucidin or fusid? *Harefuah*, 1998; 134: 420. (Not ranked).
2. Gilad J., Borer A. Treatment of acute lung injury attributed to leptospirosis. *Clinical Infectious Diseases* 2000; 31: 844 (IF=8.736; JR=2/83; Q= Q1; CI=1).
3. Gilad J. Antimycobacterial therapy for Crohn's disease. *American Journal of Gastroenterology*, 2000; 95: 2985-2986 (IF=10.383, JR=6/78, Q=Q1; CI=0).

4. Gilad J, Barnea E, Clement E. Aspirin treatment for post-vaccinal hypertrophic osteodystrophy in a Weimaraner puppy. *The Veterinary Record*, 2002; 150: 456 (IF=1.741, JR=22/138, Q=Q1; CI=2).
5. Gilad J. Pulmonary alveolar hemorrhage. *Israeli Medical Association Journal*, 2002;4:751 (IF=0.978; JR=80/151; Q=Q3; CI=0).
6. Klement E, Grotto I, Srugo I, Orr N, Gilad J, Cohen D. Pertussis in soldiers, Israel. *Emerging Infectious Diseases*, 2005; 11: 506-508 (IF=6.994; JR=4/83; Q=Q1; CI=2).
7. Borer A, Gilad J, Smolyakov R, Eskira S, Peled N, Porat N, Hyam E, Treffer R, Riesenber K, Schlaeffer F. Cell phones and *Acinetobacter* transmission. *Emerging Infectious Diseases*, 2005; 11: 1160-1161 (IF=6.994; JR=4/83; Q=Q1; CI=30).
8. Gilad J, Schwartz D. Identification of *Staphylococcus* species with VITEK-2: The case of *Staphylococcus hominis*. *Journal of Clinical Microbiology*, 2007; 45: 685-686 (IF=3.631; JR=36/123; Q=Q2; CI=4).
9. Gilad J, Schwartz D. Petri-dish Larva Migrans. *International Journal of Infectious Diseases*, 2007; 11: 468 (IF=2.229, JR=48/83, Q=Q3; CI=0).

Books and chapters in books

1. *Moran-Gilad J. *Editor* of international book on Legionella infections. Horizon Press, UK. Publication planned for end of 2017.
2. Moran-Gilad J, Saunders N. Management aspects of real-time PCR assay development. In: Logan J, Edwards K, Saunders N (eds.). *Real-time PCR: Current technology and applications*. 2nd edition, Caistre Academic Press, UK, 2013.

Published scientific reports and technical papers

1. Saunders N, Sharp I, Siddiqui R, Vipond B, Sails A, Bermingham A, Ellis J, Moran-Gilad J, Marsh P, Guiver M. Guidance on the development and validation of diagnostic tests that depend on nucleic acid amplification and detection. **United Kingdom's Health Protection Agency**, SOP Q-085/02-08, pp. 1-40, 2011.
2. Moran-Gilad J, Zambon M. Principles of a National Public Health Microbiology Response to New and Emerging Infections. **United Kingdom's Health Protection Agency**, pp. 1-10, 2011.
3. Parry JV, Threlfall EJ, Fisher IST, Hays J, Moran-Gilad J, Stapley A, Van Veen E-B. European System of Reference Laboratories for Pathogens for Humans (EU Human Pathogen Reference Laboratories Options Project [EURLOP]): Final Report. **United Kingdom's Health Protection Agency for DG SANCO – European Commission** (Contract No. SI2.553551 – SANCO/C3/2008/01), pp. 1-215, 2012.
4. Brown CS, Parry JV, Fisher IST, Moran-Gilad J, Brown C, Threlfall EJ. Improving access to EU tools relevant for cross-border health threat preparedness in Europe (EU-LabTOOLS): Final Report. **United Kingdom's Health Protection Agency and World Health Organization (WHO EURO) for European Centre for Disease Prevention and Control (ECDC)** (Contract No. OJ/07/05/2012-PROC/2012/042), pp. 1-30, 2012.
5. Moran-Gilad J, Watson J, Pebody R, Fleming D, Cottrell S, Thomas D, Smyth B, Kearns C, Ellis J, Charlett A, Domegan L, McMenamin J. United Kingdom Influenza Surveillance Harmonisation Short Life Working Group: Report 2010/11. **United Kingdom's Health Protection Agency, Health Protection Scotland, NHS Wales & HSC Northern Ireland**, pp. 1-52, 2011.
6. Moran-Gilad J, Zambon M. National Public Health Microbiology Strategy. **United Kingdom's Health Protection Agency**, pp. 1-21, 2011.

7. Moran-Gilad J, Zambon M. Reference vs. Specialist Testing in Public Health Microbiology Strategy: A proposal for Organisation of Reference Microbiology Services for England. **United Kingdom's Health Protection Agency**, pp. 1-14, 2011.
8. Moran-Gilad J, Sintchenko V, Karlsmose S, Wolfgang WJ, Pettengill J, Strain E, Hendriksen RS on behalf of Working Group 4 (GMI-WG4). Proficiency Testing for Bacterial Whole Genome Sequencing: An End-User Survey of Current Capabilities, Requirements and Priorities. **Global Microbial Identifier (GMI) Initiative**, pp. 1-32, 2014.
9. Ministry of Health. National guidelines for investigation of Legionnaires' Disease. **Ministry of Health** 2014. Available at: <http://www.health.gov.il>
10. *Hendriksen RS, Karlsmose Pedersen S, Larsen MV, Pedersen JN, Lukjancenko O, Kaas RS, Leekitcharoenphon P, Bergmark L, Hansen IM, Sintchenko V, Wolfgang WJ, Westh HK, Moran-Gilad J, Hsiao W, Cuesta I, Zaballos A, Olson ND, Beck B⁰, Underwood A, Strain E, Pettengill J and on behalf of the Global Microbial Identifier initiative's Working Group 4 (GMI-WG4); The Proficiency Testing (Pilot) Report of the Global Microbial Identifier Initiative, Year 2014. **Global Microbial Identifier (GMI) Initiative**, pp. 1-21, 2015.
11. *Rene S. Hendriksen, Susanne Karlsmose Pedersen, Mette Voldby Larsen, Jamie Neubert Pedersen, Oksana Lukjancenko, Rolf Sommer Kaas, Pimlapas Leekitcharoenphon, Lasse Bergmark, Inge Marianne Hansen, Vitali Sintchenko, William J. Wolfgang, Henrik Torkil Westh, Jacob MoranGilad, William Hsiao, Isabel Cuesta, Jorge Barrera, Angel Zaballos, Nathanael David Olson, Brian Beck, Anthony Underwood, Frank M. Aarestrup, Errol Strain, James Pettengill and on behalf of the Global Microbial Identifier initiative's Working Group 4 (GMI-WG4); The proficiency test (pilot) report of the Global Microbial Identifier Initiative Year 2014. **Global Microbial Identifier (GMI) Initiative**, pp. 1-72, 2016.
12. *Barnett-Itzhaki Z, Raanan-Kiperwas H, Reicher S, Cytryn E, Yaron S, Weinberg D, Moran-Gilad J, Agmon V, Hen I, Dosoretz CG, Sela S,

Brokovich E and Grotto I. National risk assessment of antimicrobial resistance in treated water. Experts consultation, **The Israel Society of Ecology and Environmental Sciences**, 2016, pp. 1-25.

7. Lecture and Presentations at National and International Meetings

Invited talks or invited expert / consultant

1. Moran-Gilad J. Automation in clinical microbiology. Continuing education for laboratory scientists, **Tel-Aviv University**, April 2008.
2. Moran-Gilad J. Sepsis – from bench to bedside. Continuing education for clinical laboratory directors, **Tel-Aviv University**, February 2008.
3. Moran-Gilad J. Session moderator and meeting organiser. European consultation with national microbiology focal points on reference microbiology strategy for the European Union, DG SANCO **European Commission consultation**, Athens, Greece, March 2010.
4. Moran-Gilad J. Antimicrobial resistant healthcare-associated infections. Communicable Diseases and Public Health Course, **Hebrew University School of Public Health**, Jerusalem, December 2011.
5. Moran-Gilad J. Medical aspects of Legionellosis. Conference on Legionellosis prevention, **Kfar Hamakabiah**, December 2011.
6. Moran-Gilad J. New technologies in public health microbiology. Staff meeting, **Assaf Harofeh Medical Center**, January 2012.
7. Moran-Gilad J. The role of reference laboratories in response to global health security challenges. 46th annual meeting of the **Israeli Society for Clinical Laboratory Sciences (ILMAR)**, March 2012.

8. Moran-Gilad J. Expert to European Commission consultation on public health training (ECDC). **European Commission consultation**, Verrier du lac, France, April 2012.
9. Moran-Gilad J. Strategic planning of reference microbiology activities, Staff meeting, **MOH laboratories**, Jerusalem, May 2012.
10. Moran-Gilad J. National food-borne infection prevention strategy. Periodic meeting of the **Israeli Infectious Disease Association**, October 2012.
11. Moran-Gilad J. Policy and planning for emerging infections. Hebrew University, **Hadassah Medical Center**, Jerusalem, November 2012.
12. Moran-Gilad J. Medical aspects of Legionellosis. Conference on Legionellosis prevention, **Kfar Hamakabiah**, December 2012.
13. Moran-Gilad J. Public Health Preparedness to 2012 Olympics. **MOH** staff meeting, Jerusalem, January 2013.
14. Moran-Gilad J. Ministry of Health's strategic plan for implementation of genomic technologies in public health microbiology. MOH Conference on Genomic Technologies in Public Health Microbiology, **Ben-Gurion University of the Negev**, Beer-Sheva, Israel , February 2013.
15. Moran-Gilad J. Expert to European Commission consultation on public health training (ECDC). **European Commission consultation**, Zagreb, Croatia, May 2013.
16. Moran-Gilad J. Policy consideration for screening blood products for West Nile Virus. National Conference on Emerging Viral Zoonoses, **Ministry of Health**, Tel-Hashomer, June 2013.
17. Moran-Gilad J. Chairmanship of session on One Health. National Conference on Emerging Viral Zoonoses, **Ministry of Health**, Tel-Hashomer, June 2013.
18. Moran-Gilad J. Policy consideration for screening blood products for West Nile Virus. **National Conference on Blood Banking**, Ramat Gan, July 2013.

19. Moran-Gilad J. Syndromic presentation of bioterrorism agents. Staff meeting, **Soroka University Medical Center**, Beer-Sheva, October 2013.
20. Moran-Gilad J. Expert to European Centre for Disease Control consultation on public health response to poliomyelitis (ECDC). **European Commission consultation**, Stockholm, Sweden, November 2013.
21. Moran-Gilad J. Foodborne listeriosis in pregnancy. Staff meeting, **Soroka University Medical Center**, Beer-Sheva, December 2013
22. Moran-Gilad J. Molecular diagnostics: when to use and when not to use. **ESCMID Post-Graduate Course in Molecular Microbiology**, Maastricht, The Netherlands, March 2014.
23. Moran-Gilad J and Raymaekers M. Chair and Speaker at the Meet-the-Expert session on troubleshooting of molecular diagnostics in the clinical microbiology laboratory. **24th European Conference on Clinical Microbiology and Infectious Diseases (ECCMID)**, Barcelona, Spain, May 2014.
24. *Moran-Gilad J. Rapid spread and control of wild poliovirus in a highly IPV-vaccinated population – the Israel experience. **3rd ESCMID Conference on Vaccines – vaccines for mutual protection**, Lisbon, Portugal, March 2015.
25. *Moran-Gilad J. Keynote Talk - A Review of emerging laboratory strategies for detection, investigation and characterisation of *Legionella*. **3rd ESGLI meeting (ESCMID Study Group for Legionella Infections)**, London, United Kingdom, September 2015.
26. *Moran-Gilad J. Application of WGS for characterization of *Acinetobacter spp.* **ESCMID Capacity-building Workshop: Rapid NGS for Characterization and Typing of Resistant Gram-Negative Bacilli**, Groningen, The Netherlands, October 2015.

27. *Moran-Gilad J. Keynote speaker at Eurosurveillance Seminar. 'Finding the Right Tool for the Job – Advanced Diagnostics in Outbreak Management and Response'. **European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE)**, Stockholm, Sweden, November 2015.
28. *Moran-Gilad J. Session Moderator. 'Public Health Microbiology and Molecular Epidemiology'. **European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE)**, Stockholm, Sweden, November 2015
29. *Moran-Gilad J. Workshop - The basics of NGS (with John WA Rossen). **ESCMID Post-Graduate Course in Molecular Microbiology**, Maastricht, The Netherlands, January 2016.
30. *Moran-Gilad J. Workshop - The steps in NGS (with Mark Eloit). **ESCMID Post-Graduate Course in Molecular Microbiology**, Maastricht, The Netherlands, January 2016.
31. *Moran-Gilad J. Workshop – Typing, resistance and virulence (with Alexander Mellman). **ESCMID Post-Graduate Course in Molecular Microbiology**, Maastricht, The Netherlands, January 2016.
32. *Moran-Gilad J. Genomic microbiology for Legionnaires' disease cluster investigation. **11th International Meeting on Microbial Molecular Markers (IMMEM-11)**, Estoril, Portugal, March 2016.
33. *Moran-Gilad J. Legionnaires' disease in Israel. **Special Seminar – 40 years for Legionnaires' disease**. Public Health England, London, United Kingdom, March 2016.
34. *Moran-Gilad J. Quality Control of molecular diagnostics – implications for forensic microbiology. **ESCMID Post-Graduate Technical Workshop – Molecular Diagnostics in Forensic Microbiology**, Leuven, Belgium, June 2016.

Oral presentations at scientific meetings

1. Menashe G, Borer A, Peled N, Gilad J, Riesenber K, Schlaeffer F, Alkan M, Yagupsky P. Clinical significance and impact on mortality of ESBL-producing gram-negative isolates in nosocomial bacteremia. **The 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Francisco, USA, September 1999.
2. Gilad J, Borer A, Peled N, Riesenber K, Schlaeffer F. Epidemiology and ethnic distribution of drug-resistant tuberculosis in southern Israel 1992-1997: The impact of immigration. **The 2nd Scientific Conference on Quality in Healthcare**, Beer-Sheva, Israel, May 2000.
3. Borer A, Fuchs I, Peled N, Gilad J, Schlaeffer F, Riesenber K, Yagupsky P. Increasing antibiotic resistance among *Streptococcus pneumoniae* isolates from adult patients in southern Israel. **The 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Toronto, Canada, September 2000.
4. Borer A, Gilad J, Schlaeffer P, Schlaeffer F, Riesenber K, Meydan N. A proposed original tool for the standardized assessment of appropriateness of antibiotic therapy. **The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Chicago, USA, December 2001.
5. Borer A, Klein M, Peled N, Weksler N, Schlaeffer P, Schlaeffer F, Eskira S, Gilad J, Gurman G. Control of multi-drug resistant *Acinetobacter baumannii* using an empiric infection control model. **The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Diego, USA, September 2002.
6. Gilad J, Borer A, Smolyakov R, Riesenber K, Schlaeffer F, Levy R. Impaired chemotaxis in the pathogenesis of recurrent furunculosis among mentally-retarded adults. **Annual Meeting of the Israeli Infectious Disease Association**, Zefad, Israel, June 2003.

7. Borer A, Gilad J, Megreleshvili R, Eskira S, Peled N, Schlaeffer F, Almog Y. Prevalence and control of *Acinetobacter baumannii* skin colonization among medical intensive-care unit patients. **The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Chicago, USA, September 2003.
8. Borer A, Hyam E, Schlaeffer F, Eskira S, Klein M, Gurman G, Peled N, Gilad J. Effect of Patient Cohorting on Nosocomial Isolates in a Surgical Intensive-Care Unit (SICU). **The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, October 2004.
9. Borer A, Buchnik L, Golan A, Hyam E, Gilad J. Safety and efficacy of 2% chlorhexidine tincture for prevention of catheter-related bloodstream infection in the neonatal intensive-care unit. **The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, December 2005.
10. Borer A, Gilad J, Nativ R, Peled N, Shprecher H, Wiznitzer A, Hyam E, Riesenber K, Schlaeffer F, Greenberg D. A nosocomial outbreak of Pontiac Fever among hospital personnel. **The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, December 2005.
11. Borer A, Peled N, Golan A, Buchnik L, Hyam E, Gilad J. Impact of weekly personnel hand cultures on incidence of nosocomial bloodstream infections. **The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, December 2005.
12. Kopilov U, Admon G, Borer A, Schlaeffer F, Aviram EE, Gilad J. Auditing and benchmarking of azithromycin utilization in military clinics. **The 8th National Conference, Israeli Society for Quality**, Tel-Aviv, Israel, December 2005.

13. Gilad J. Pre-hospital administration of antimicrobial therapy for open fractures. **The 1st National Conference on Frontier Medicine**, Eilat, May 2009.
14. Wain J, Nair S, Peters T, Moran Gilad J. Harnessing novel technologies in public health microbiology: development of a rapid multiplex SNP-based method for rapid *Salmonella* sub-typing. **Annual Meeting of the Israeli Infectious Disease Association**, Jerusalem, Israel, June 2011.
15. Moran-Gilad J, Goldmann D, Anis E. Ministry of Health guidelines for international travel – update 2011. **Annual meeting of the Israeli Society for Parasitology, Protozoology and Tropical Diseases (ISPPTD)**, Ramat Gan, Israel
December 2011.
16. Moran-Gilad J. Waterborne infections and mass gatherings: The case of rapid laboratory diagnosis of leptospirosis. **Annual meeting of the Israeli Society for Parasitology, Protozoology and Tropical Diseases (ISPPTD)**, Ramat Gan, Israel, December 2011.
17. Moran Gilad J. Harnessing novel technologies in public health microbiology: development of a rapid multiplex SNP-based method for rapid *Salmonella* sub-typing. **Annual Meeting of the Israeli Society for Microbiology (ISM)**, Bar-Ilan University, Israel, February 2011.
18. Moran Gilad J on behalf of EURLOP. The EURLOP Project – Envisioning a Public Health Reference Microbiology Laboratory System for Europe. **Annual Meeting of the Israeli Infectious Disease Association**, Nazareth, Israel, May 2012.
19. Moran-Gilad J, Lazarovitch T, Mentasti M, Harrison T, Weinberger M, Mordish Y, Mor Z, Anis E, Sadik C, Grotto I. Public Health Implications of a Fatal Paediatric Legionellosis Case Associated with an Unusual Transmission Route. 1st **ESGLI** meeting (ESCMID Study Group for Legionella Infections), Dresden, Germany, September 2012.

20. Mor Z, Gandacu D, Kacher Y, Chemtob D, Dveyrin Z, Alon T, Dan M, Guberman D, Anis E, Rorman E, Moran-Gilad J. Surveillance, diagnosis and treatment of sexually transmitted infections in Israel – A strategic view. **National conference on STIs** (A decade to the Levinsky STI clinic), Ramat Ef'al, Israel, October 2012.
21. Moran-Gilad J. Molecular epidemiology of Legionnaires' disease in Israel, 2006-2011. **National Conference on Public Health Aspects of Legionellosis**, Tel-Hashomer, Israel, December 2012.
22. Moran-Gilad J, Valinsky L, Agmon V, Yoni Y, Zagron G, Gordon E, Shahar T, Sadik C, Anis E, Grotto I. The Ministry of Health Strategic Plan for Control of Listeriosis. Annual Conference of the **Israeli Association for Veterinary Immunology and Microbiology (IVAMI)**, Beit Dagan, Israel, January 2013.
23. Moran-Gilad J, Valinsky L, Agmon V, Yoni Y, Zagron G, Gordon E, Shahar T, Sadik C, Anis E, Grotto I. The Ministry of Health Strategic Plan for Control of Listeriosis. Annual Conference of the **Israeli Association for Infectious Diseases**, Mitzpe Ramon, Israel, February 2013.
24. Moran-Gilad J, Hindiyeh M, Manor Y, Shulman L, Kaliner E, Grotto I, Sofer D, Mendelson E. Intensified environmental surveillance supporting the response to wild-type poliovirus 1 silent circulation in Israel, 2013. European Scientific Conference on Applied Infectious Disease Epidemiology (**ESCAIDE**), Stockholm, Sweden, October 2013.
25. Moran-Gilad J. Lessons learned from tick borne relapsing fever outbreaks in Israel. **Annual conference on medical research, IDF Medical Corps**, Jerusalem, Israel. October 2013.
26. Moran-Gilad J. Field studies of poliovirus excretion and exposure as decision-support tools. **International preparedness & response to emergencies & disasters (IPRED III)**, Tel-Aviv, Israel, January 2014.

27. Harmsen D, Prior K, Yakunin E, Valinsky L, Agmon V, Grotto I, Moran-Gilad J. Application of Whole Genome Sequence (WGS) Analysis of *Legionella pneumophila* Strains (Lp) for Investigation of Legionnaires' Disease (LD) Clusters. **Annual Conference of the Israeli Association for Infectious Diseases**, Ramot, Israel, May 2014.
28. Harmsen D, Prior K, Yakunin E, Valinsky L, Agmon V, Grotto I, Moran-Gilad J. Comparison of bioinformatics approaches for whole genome sequencing analysis of Legionnaires' disease clusters. **24th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Barcelona, Spain, May 2014.
29. Rokney A, Anuka E, Barzilay O, Moran-Gilad J, Agmon V, Valinsky L. Emergence of EMRSA-15 as a significant cause of *S. aureus* bacteremia in Israel. **24th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Barcelona, Spain, May 2014.
30. Weinberger M, Agmon V, Lerner L, Antebi Y, Davidov Y, Rokney A, Moran-Gilad J, Valinsky L. Multilocus sequence typing (MLST)-based phylogenetic analysis and source attribution of *Campylobacter jejuni* clinical isolates from Israel. **Annual Conference of the Israeli Association for Infectious Diseases**, Ramot, Israel, May 2014.
31. Moran-Gilad J. Application of genomic technologies for brucellosis control. Ministry and Health and Ministry of Agriculture. **National Conference on Brucellosis Control**, Beit Dagan, Israel, November 2014.
32. *Gordon M, Dassa B, Carrico JA, Marchaim D, Lazarovitch L, Valinsky L, Chalifa-Caspi V, Moran-Gilad J. Application of Whole Genome Sequencing for Streamlined Identification and Susceptibility Testing (ID/AST) of Carbapenem-Resistant *Acinetobacter spp.* **25th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Copenhagen, Denmark, April 2015.

33. *Marchaim D, Zigran R, Gordon M, Dassa B, Lazarovitch L, Silva M, Carrico JA, Chalifa-Caspi V, Moran-Gilad J. Clinical and molecular epidemiology of *Acinetobacter baumannii* bloodstream infections. **25th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Copenhagen, Denmark, April 2015.
34. *Petzold M, Prior K, Moran-Gilad J, Harmsen D, Luck C. Retrospective investigation of the largest German Legionella pneumophila outbreak to date in Warstein (2013) by core genome MLST revealed two different clones as causative agents. **3rd ESGLI meeting (ESCMID Study Group for Legionella Infections)**, London, United Kingdom, September 2015.
35. *Petzold M, Prior K, Moran-Gilad J, Harmsen D, Luck C. Retrospective investigation of the largest German Legionella pneumophila outbreak to date in Warstein (2013) by core genome MLST revealed two different clones as causative agents. **67th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM)**, Munster, Germany, September 2015.
36. *Levy E, Gilad N, Gordon M, Marchaim D, Carrico JA, Ziv-Ukelson M, Chalifa-Caspi V, Moran-Gilad J. Streamlined Genomic Approaches for Studying Virulence Markers in *Acinetobacter baumannii* (Ab). **26th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Amsterdam, The Netherlands, April 2016.
37. *Gilad N, Ziv-Ukelson M, Chalifa-Caspi V, Moran-Gilad J. Practicability of Molecular Typing Scheme for *Staphylococcus aureus* in the Genomic Era. **26th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Amsterdam, The Netherlands, April 2016.
38. *Clifford R, Chukwuma U, Neumann C, Waterman P, Milburn E, Moran-Gilad J, Julius M, Hinkle M, Lesho E. SAVE'M STAT: Staph Aureus Vancomycin Evaluation of MIC, A Semi-automated Tool for Analyzing Trends. **The Society for Healthcare Epidemiology of America (SHEA) 2016 Conference**, Atlanta, GA, USA, May 2016.

39. *Clifford R, Sparks M, Chukwuma U, Neumann C, Waterman P, Milburn E, Moran-Gilad J, Julius M, Hinkle M, Lesho E. Regular Evaluation of Vancomycin for Automated MIC Problems (Revamp): Trending of Vancomycin Minimum Inhibitory Concentrations Across Healthcare Enterprises **American Society for Microbiology (ASM Microbe) 2016**, Boston, MA, USA, June 2016.
40. *Gilad N, Ziv-Ukelson M, Chalifa-Caspi V, Moran-Gilad J. A clinically-relevant pipeline for analysis of *S. aureus* whole genome sequences. **Annual Conference of the Israeli Association for Infectious Diseases**, Ramot, Israel, May 2016.

Poster presentations at scientific meetings

1. Riesenber K, Gilad J, Borer A, Weber G, Alkan M, Schlaeffer F. Bedouin origin as a risk factor for Varicella pneumonia in adults. **8th International Congress on Infectious Diseases (ICID)**, Boston, USA, May 1998.
2. Mana H, Gilad J, Schlaeffer F, Mermershtain W, Porath A, Riesenber K. Adjuvant treatment with Granulocyte-colony stimulating factor (G-CSF) in neutropenic fever. **The 10th International Symposium on Infections in the Immunocompromised Host (ICHS)**, Davos, Switzerland, June 1998
3. Gilad J, Riesenber K, Mermershtain W, Borer A, Porath A, Schlaeffer F. Prophylactic Granulocyte-colony stimulating factor (G-CSF) for the prevention of chemotherapy-induced febrile neutropenia. **The 10th International Symposium on Infections in the Immunocompromised Host (ICHS)**, Davos, Switzerland, June 1998.
4. Borer A, Yagupsky P, Peled N, Riesenber K, Shipman M, Gilad J, Schlaeffer F. *De-novo* emergence and dissemination of a methicillin-resistant *Staphylococcus aureus* strain in a long-term care facility in southern Israel. **The 38th Interscience Conference on Antimicrobial Agents and**

- Chemotherapy (ICAAC)**, San Diego, USA, September 1998.
5. Borer A, Gilad J, Haikin H, Riesenber K, Porath A, Schlaeffer F. Impact on healthcare expenses of primary infection with the Epstein-Barr virus in hospitalized adult patients. **The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Diego, USA, September 1998.
 6. Borer A, Schlaeffer F, Riesenber K, Gilad J, Konforti A, Levy R. The role of disturbed neutrophil function in mentally-retarded adults during an outbreak of furunculosis. **The 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Francisco, USA, September 1999.
 7. Gilad J, Borer A, Peled N, Riesenber K, Schlaeffer F. Epidemiology and ethnic distribution of drug-resistant tuberculosis in southern Israel 1992-1997: The impact of immigration. **The 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Francisco, USA, September 1999.
 8. Borer A, Gilad J, Schlaeffer P, Riesenber K, Schlaeffer F, Alkan M. Impact of active monitoring of infection control practices among personnel on the rate of surgical-site infection following open-heart surgery. **The 38th Infectious Disease Society of America (IDSA) Meeting**, Philadelphia, USA, November 1999.
 9. Smolyakov R, Riesenber K, Alkan M, Borer A, Gilad J, Peled N, Schlaeffer F. Till death do us part – Streptococcal necrotizing fasciitis in a couple of intravenous drug users sharing needles. **The 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Toronto, Canada, September 2000.
 10. Gilad J, Borer A, Schlaeffer P, Schlaeffer F, Riesenber K, Meydan N. Community-acquired urinary tract infection (UTI) in southern Israel: Things are getting worse. **The 40th Interscience Conference on Antimicrobial**

Agents and Chemotherapy (ICAAC), Toronto, Canada, September 2000.

11. Borer A, Meydan N, Schlaeffer P, Gilad J, Riesenberg K, Schlaeffer F. Impact of infectious disease specialists on the management of hospitalized febrile adults. **The 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Toronto, Canada, September 2000.
12. Borer A, Gilad J, Schlaeffer P, Riesenberg K, Schlaeffer F, Alkan M. Impact of active monitoring of infection control practices among personnel on the rate of surgical-site infection following open-heart surgery. **The 2nd Annual Israeli Conference for Health Policy**, Ramat-Gan, Israel, December 2000.
13. Smolyakov R, Riesenberg K, Borer A, Gilad J, Alkan M, Schlaeffer F. Risk factors for bloodstream infection with multi-drug resistant *Acinetobacter baumannii*. **The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Diego, USA, September 2002.
14. Melamed R, Zmora E, Peled N, Schlaeffer P, Eskira S, Gilad J, Borer A. Preliminary results of measures to control bloodstream infections in a neonatal intensive-care unit. **The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Diego, USA, September 2002.
15. Borer A, Katz A, Schlaeffer P, Gilad J*, Riesenberg K, Eskira S, Schlaeffer F. Reduction of cardiac pacemaker-associated infections by implementation of infection control measures. **The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Diego, USA, September 2002.
16. Moran L, Gilad J, Borer A, Meydan N, Schlaeffer F. Features of antibiotic drug advertisements in medical journals. **The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Diego, USA, September 2002.

17. Golzman G, Riesenberk K, Krap E, Borer A, Gilad J, Porath A, Schlaeffer F. Risk factors for mortality in community-acquired complicated parapneumonic effusion. **The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Diego, USA, September 2002.
18. Nesher L, Riesenberk K, Borer A, Gilad J, Schlaeffer F. Species distribution and antibiotic resistance patterns among hospitalized patients with ascending urinary tract infections. **The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Diego, USA, September 2002.
19. Hadad E, Pirogovsky A, Bartal C, Gilad J, Barnea A, Itzhaki S, Grotto I, Balicer R, Schwartz E. An outbreak of leptospirosis among Israeli troops in the Jordan River. **Annual Meeting of the Israeli Infectious Disease Association**, Zefad, Israel, June 2003.
20. Gilad J, Eskira S, Schlaeffer F, Vorobiov A, Marcovici D, Tovbin A, Borer A. Surveillance of chronic hemodialysis-associated infections in southern Israel. **The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Chicago, USA, September 2003.
21. Smolyakov R, Schlaeffer F, Gabriel A, Gilad J, Riesenberk K, Borer A, Golzman G, Cherniavsky E, Smolikov A. Prevalence and implication of the suspended microbubble sign in computed tomographic scan of thoracic empyema. **The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Chicago, USA, September 2003.
22. Borer A, Gilad J, Megreleshvili R, Hyam E, Peled N, Eskira S, Schlaeffer F, Almog Y. Control of gram-negative bloodstream infections in a medical intensive-care unit. **The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Chicago, USA, September 2003.

23. Borer A, Klein M, Gilad J, Peled N, Weksler N, Schlaeffer F, Eskira S, Gurman G. Impact of antibiotic class restriction on multidrug resistant gram-negative isolates. **The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Chicago, USA, September 2003.
24. Borer A, Smolyakov R, Eskira S, Peled N, Gilad J, Man L, Hyam E, Riesenber K, Schlaeffer F. Cellular phones of personnel as a potential source for nosocomial transmission of *Acinetobacter baumannii*. **The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Chicago, USA, September 2003.
25. Gilad J, Borer A, Smolyakov R, Riesenber K, Schlaeffer F, Levy R. Impaired chemotaxis in the pathogenesis of recurrent furunculosis among mentally-retarded adults. **The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Chicago, USA, September 2003.
26. Gilad J, Moran L, Schlaeffer F, Borer A. Features of antibiotic drug advertisements in medical journals. **The 4th Annual Israeli Conference for Health Policy**, Tel-Aviv, Israel, December 2003.
27. Hyam E, Wiznitzer A, Borer A, Schlaeffer P, Schlaeffer F, Cohen G, Gilad J. Handling the Media During a Nosocomial Crisis. **The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, October 2004.
28. Hyam E, Borer A, Schlaeffer P, Gilad J, Shemer Y, Nativ R, Sikuler E, Delgado J, Barbi T, Riesenber K, Schlaeffer F. Perioperative Transmission of Hepatitis C Virus (HCV) Type 2AC Linked to a Seropositive Anesthetist. **The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, October 2004.
29. Borer A, Eskira S, Gilad J, Schlaeffer P, Hyam E, Peled N, Riesenber K, Schlaeffer F. An Educational Intervention for Reduction of Blood Culture

- Contamination (BCC). **The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, October 2004.
30. Gilad J, Kraim P, Megreleshvili R, Almog Y, Schlaeffer P, Schlaeffer F, Peled N, Hyam E, Borer A, Eskira S. Impact of Vascular Catheter (VC) Insertion Site (IS) Care on Catheter-Related Bloodstream Infections (CRBSI). **The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, October 2004.
31. Gilad J, Schlaeffer F, Eskira S, Peled N, Hyam E, Borer A. Emergence of Nosocomial Carbapenem-Resistant *Escherichia coli* (CR-EC): A Case-Control Study. **The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, October 2004.
32. Gilad J, Eskira S, Schlaeffer F, Peled N, Riesenber K, Hyam E, Seyman E, Elalouf O, Borer A. Antibiotic resistance among nosocomial *Enterobacteriaceae* in southern Israel. **The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, December 2005.
33. Gilad J, Eskira S, Riesenber K, Schlaeffer F, Hyam E, Borer A. Emergence of nosocomial colistin-resistant *Acinetobacter baumannii*. **The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, December 2005.
34. Riesenber K, Karp E, Schlaeffer F, Borer A, Gilad J. Recovery of CD4 cell counts among patients infected with HIV-1 subtype C. **The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, Washington DC, USA, December 2005.
35. Riesenber K, Grossman Z, Schlaeffer F, Levy E, Mileguir F, Kra-Oz Z, Borer A, Gilad J, Karp E, Shemer-Avni Y. Discordance between two commercial viral load assays in patients infected with HIV-1 subtype A. **The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy**

- (ICAAC), Washington DC, USA, December 2005.
36. Gilad J, Gul M, Giladi M, Schwartz D. Discrepant Susceptibility Results of *Streptococcus pneumoniae* to Ceftriaxone and Cefotaxime: Implications for Vancomycin Treatment of meningitis. **The 107th General Meeting, American Society for Microbiology (ASM)**, Toronto, Canada, May 2007.
37. Schwartz D, Gul M, Giladi M, Gilad J. Microbiologic Features of *Streptococcus pneumoniae* (SP) Infection Among Adult patients in Metropolitan Tel-Aviv. **The 107th General Meeting, American Society for Microbiology (ASM)**, Toronto, Canada, May 2007.
38. Gilad J, Schwartz D. Evaluation of a Malaria Antigen Rapid Diagnostic Test (RDT) in a Non-Endemic Setting. **The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / Infectious Disease Society of America (IDSA)**, Washington DC, USA, October 2008.
39. Gilad J, Uralelev B, Schwartz D. Need for Verification of Imipenem (IPM), Meropenem (MER) and Amikacin (AK) VITEK-2 Susceptibility Results for *Acinetobacter baumannii* (Ab)? **The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / Infectious Disease Society of America (IDSA)** , Washington DC, USA, October 2008.
40. Gilad J, Schwartz D, Carmeli Y, Navon-Venezia S. Laboratory evaluation of media for isolation of carbapenem-resistant *Acinetobacter baumannii*. **The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Francisco, USA, September 2009.
41. Marcos E, Gilad J, Stepansky S, Schwartz D, Smollan G, Schwaber MJ, Carmeli Y, Navon-Venezia S. Evaluation of screening agar plates for detection of carbapenem-resistant *Klebsiella pneumoniae* (CRKP). **The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)**, San Francisco, USA, September 2009.

42. Gilad J, Schwartz D, Navon-Venezia S, Carmeli Y. Performance of the ESwab Transport System for Recovery of *Acinetobacter baumannii*. **5th Decennial International Conference on Healthcare-Associated Infections**, Atlanta, USA, March 2010.
43. Gilad J, Schwartz D, Navon-Venezia S, Carmeli Y. Laboratory evaluation of the ESwab Transport System for Recovery of multi-drug resistant *Acinetobacter baumannii* from fecal specimens. **5th Decennial International Conference on Healthcare-Associated Infections**, Atlanta, USA, March 2010.
44. Gilad J, Chmelnitsky I, Schwartz D, Carmeli, Y Navon-Venezia S. Molecular mechanisms underlying carbapenem-resistant *Acinetobacter baumannii* in Tel-Aviv. **5th Decennial International Conference on Healthcare-Associated Infections**, Atlanta, USA, March 2010.
45. Moran Gilad J, Lackenby A, Zambon M. Emergence and spread of oseltamivir-resistant influenza A (H1N1) 2009 in the UK, 2010/11: Implications on surveillance and treatment policies. **Annual Meeting of the Israeli Infectious Disease Association**, Jerusalem, Israel, June 2011.
46. Parry JV, Fisher I, Hays J, Moran Gilad J, Threlfall EJ, Stapley A, van Veen EB, Zambon M. The EURLOP Project – Envisioning a Public Health Reference Microbiology Laboratory System for Europe. **Health Protection 2011**, Warwick, UK, September 2011.
47. Lackenby A, Moran-Gilad J, Pebody R, Miah S, Calatayud L, Bolotin S, McMenamin J, Reynolds A, Moore C, Gunson R, Ellis J, Zambon M. Continued emergence and changing epidemiology of oseltamivir-resistant H1N1 (2009) influenza, UK 2010/11. **The 4th ESWI Influenza Conference**, Malta, September 2011.

48. Brown CS, Parry JV, Fisher I, Moran Gilad J, Brown C, ECDC Microbiology Coordination Section, Threlfall EJ. EU-LabCAT Project–Developing a tool for assessment of European Public Health Reference Microbiology capability and capacity. **Health Protection 2012**, Warwick, UK, September 2012.
49. Brown CS, Parry JV, Fisher I, Moran Gilad J, Brown C, ECDC Microbiology Coordination Section, Threlfall EJ. EU-LabCAT Project–The development of a tool for assessment of European Public Health Reference Microbiology capability and capacity. **European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE)**, Edinburgh, UK, October 2012.
50. Nissan I, Schorr YI, Jaffe J, Agmon V, Reisfeld A, Moran-Gilad J, Valinsky L. Emergence of multidrug resistant *Salmonella enterica* serovar Kentucky in Israel. **Annual Meeting of the Israeli Society for Microbiology (ISM)**, Bar-Ilan University, Israel, February 2013.
51. Ezernitchi A, Moran-Gilad J, Agmon V, Yoni Y, Yaffe J, Nissan I, Valinsky L. Laboratory based surveillance of circulating serotypes and clone types of *Listeria monocytogenes* in Israel. **Annual Meeting of the Israeli Society for Microbiology (ISM)**, Bar-Ilan University, Israel, February 2013.
52. Moran-Gilad J, Mentasti M, Lazarovitch Z, Huberman Z, Stocki T, Sadik C, Shahar T, Anis E, Harrison TG, Grotto I. Molecular epidemiology of Legionnaires' Disease in Israel. **Annual Conference of the Israeli Association for Infectious Diseases**, Mitzpe Ramon, Israel, February 2013.
53. Moran-Gilad J, Valinsky L, Agmon V, Yoni Y, Zagron G, Gordon E, Shahar T, Sadik C, Anis E, Grotto I. The Ministry of Health Strategic Plan for Control of Listeriosis. **23rd European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Berlin, Germany, April 2013.

54. Moran-Gilad J, Mentasti M, Lazarovitch Z, Huberman Z, Stocki T, Sadik C, Shahar T, Anis E, Harrison TG, Grotto I. Molecular epidemiology of Legionnaires' Disease in Israel. **23rd European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Berlin, Germany, April 2013.
55. Moran-Gilad J, Mentasti M, Lazarovitch Z, Huberman Z, Stocki T, Sadik C, Shahar T, Anis E, Harrison TG, Grotto I. Molecular epidemiology of Legionnaires' Disease in Israel. **10th International Meeting on Microbial Molecular Markers (IMMEM-10)**, Paris, France, October 2013.
56. Moran-Gilad J, Manor Y, Bassal R, Hindiyeh M, Kaliner E, Sofer D, Weil M, Gdalevich M, Grotto I, Mendelson E. Monitoring of Immunisation Effect on Wild Poliovirus 1 (WPV1) Circulation Using Complementary Environmental and Stool Surveillance Following Reintroduction into Israel. **Annual Conference of the Israeli Association for Infectious Diseases**, Ramot, Israel, May 2014.
57. Harmsen D, Prior K, Yakunin E, Harrison TG, Valinsky L, Krux F, Lazarovitch T, Mentasti M, Grotto I, Moran-Gilad J. Whole genome sequencing investigation of household water filtrators and cold water humidifiers as emerging vehicles for paediatric Legionnaires' disease. **24th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Barcelona, Spain, May 2014.
58. Mendelson E, Moran-Gilad J, Manor Y, Bassal R, Hindiyeh M, Kaliner E, Sofer D, Weil M, Gdalevich M, Grotto I. Monitoring of supplementary immunisation effect on wild Poliovirus circulation using complementary environmental and stool Surveillance approaches following reintroduction of wild Poliovirus 1 into Israel. **24th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Barcelona, Spain, May 2014.
59. Moran-Gilad J, Mendelson E, Burns CC, Bassal R, Gdalevich M, Oberste MS, Shulman L, Kaliner E, Sofer D, Grotto I. Field study of faecal excretion as

- decision support tool in response to silent reintroduction of wild Poliovirus 1 into Israel. **24th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Barcelona, Spain, May 2014.
60. Rokney A, Anuka E, Davidovich-Cohen M, Barzilay O, Moran-Gilad J, Agmon V, Valinsky L. Molecular epidemiology of methicillin-resistant *S. aureus* strains from skin and soft tissue infections in Israel. **24th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Barcelona, Spain, May 2014.
61. Harrison TG, Moran-Gilad J, Mentasti M, David S, Afshar B, Andersen PS, Stegger, M, Valinsky, L, Yakunin, Uldum SA. Use of whole genome sequence (WGS) data to investigate anomalies in the ESGLI *Legionella pneumophila* DNA-sequence based typing (SBT) method. **2nd ESCMID Study Group for Legionella Infections meeting (ESGLI)**, Barcelona, Spain, September 2014.
62. *Gordon M, Silva M, Dassa B, Carrico JA, Marchaim D, Lazarovitch L, Valinsky L, Chalifa-Caspi V, Moran-Gilad J. A proposed novel high-resolution core genome multi-locus sequence typing scheme for *Acinetobacter baumannii*. **25th European Conference on Clinical Microbiology & Infectious Diseases (ECCMID)**, Copenhagen, Denmark, April 2015.
63. *Gilad N, Ziv-Ukelson M, Chalifa-Caspi V, Moran-Gilad J. Characteristics of publicly available *S. aureus* genomes. **11th International Meeting on Microbial Molecular Markers (IMMEM-XI)**, Estoril, Portugal, March 2016.
64. *Silva M, Carrico JA, Gilad N, Gordon M, Ramirez M, Chalifa-Caspi V, Moran-Gilad J. Appraisal of Complementary Strategies for Refinement of a Core Genome Multi-Locus Sequence Typing Scheme for Typing of *Acinetobacter baumannii*. **11th International Meeting on Microbial Molecular Markers (IMMEM-XI)**, Estoril, Portugal, March 2016.